# MYELOMA CELL HETEROGENEITY AND IMMUNOREGULATION

> **NIH NIH R01** · UNIVERSITY OF IOWA · 1989 · $135,069

## Abstract

The long-term objective of the proposed research is to learn
more about the roles of iron, transferrin, and the transferrin
receptor in the processes of lymphocyte activation, and to
develop a model to explain the effects of IgG anti-transferrin
receptor antibodies (ATRAS) on those processes.

Our specific aims are to test the hypotheses that 1) lymphocyte
subsets differ in their requirements for uptake of transferrin
bound iron for growth, 2) IgG-ATRAS differ in their capacity to
reduce transferrin receptor expression and the iron uptake
function, and 3) our recently developed IgG ATRA, C2F2,
reduces TR expression (and iron uptake function) to a degree
such that it produces a unique, highly selective pattern of
inhibition of lymphocyte activation protocols.

The following methodology will be used in testing our
hypotheses.  Lymphocyte subsets will be purified by cytotoxic
depletion, plate panning, and Percoll gradient banding.  Helper
and cytotoxic T cell clones will also be employed.  59Fe iron
uptake will be measured in serum-free media, and net iron
uptake per S phase entry for a given cell type will be derived
with the use of flow cytometric cell-cycle analysis and
colchicine treatment of lymphocyte cultures.  IgG ATRA effects
on TR expression will be assessed by flow cytometry.  IgG ATRA
effects on lymphocte activation protocols will be studied in the
MLR, in IL-1 and IL-2-dependent T cell growth assays, and in
Con A, PHA, and LPS mitogen induced growth assays.

The health relatedness of this proposal derives from the fact of
the normal immune response is disturbed under conditions of iron
deficiency and iron overload.  Major restributions of iron stores
in the reticuloendothelial system are characteristic of acute and
chronic inflammation and striking alterations of iron metabolism
occur in several neoplastic diseases.  The proposed studies will
contribute to our understanding of these problems.

## Key facts

- **NIH application ID:** 3175085
- **Project number:** 5R01CA037252-05
- **Recipient organization:** UNIVERSITY OF IOWA
- **SAM.gov UEI:** Z1H9VJS8NG16
- **Principal Investigator:** JOHN D KEMP
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1989
- **Award amount:** $135,069
- **Award type:** 5
- **Project period:** 1984-07-01 → 1991-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3175085

## Citation

> US National Institutes of Health, RePORTER application 3175085, MYELOMA CELL HETEROGENEITY AND IMMUNOREGULATION (5R01CA037252-05). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3175085. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*